company background image
ENOB

Enochian BiosciencesNasdaqCM:ENOB Stock Report

Market Cap

US$655.4m

7D

19.2%

1Y

337.3%

Updated

01 Dec, 2021

Data

Company Financials
ENOB fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health2/6
Dividends0/6

ENOB Stock Overview

Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer.

Price History & Performance

Summary of all time highs, changes and price drops for Enochian Biosciences
Historical stock prices
Current Share PriceUS$12.55
52 Week HighUS$12.99
52 Week LowUS$2.80
Beta0.60
1 Month Change34.66%
3 Month Change67.33%
1 Year Change337.28%
3 Year Change80.58%
5 Year Changen/a
Change since IPO83.21%

Recent News & Updates

Oct 30
Enochian Biosciences (NASDAQ:ENOB) Has Debt But No Earnings; Should You Worry?

Enochian Biosciences (NASDAQ:ENOB) Has Debt But No Earnings; Should You Worry?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Shareholder Returns

ENOBUS BiotechsUS Market
7D19.2%1.3%-2.8%
1Y337.3%4.1%20.0%

Return vs Industry: ENOB exceeded the US Biotechs industry which returned 4.1% over the past year.

Return vs Market: ENOB exceeded the US Market which returned 20% over the past year.

Price Volatility

Is ENOB's price volatile compared to industry and market?
ENOB volatility
ENOB Average Weekly Movement8.8%
Biotechs Industry Average Movement8.6%
Market Average Movement6.0%
10% most volatile stocks in US Market15.0%
10% least volatile stocks in US Market2.3%

Stable Share Price: ENOB is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: ENOB's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201711Mark Dybulhttps://www.enochianbio.com

Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company’s lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection.

Enochian Biosciences Fundamentals Summary

How do Enochian Biosciences's earnings and revenue compare to its market cap?
ENOB fundamental statistics
Market CapUS$655.36m
Earnings (TTM)-US$34.74m
Revenue (TTM)n/a

0.0x

P/S Ratio

-18.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ENOB income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
ExpensesUS$34.74m
Earnings-US$34.74m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.67
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio3.5%

How did ENOB perform over the long term?

See historical performance and comparison

Valuation

Is Enochian Biosciences undervalued compared to its fair value and its price relative to the market?

3.92x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ENOB's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ENOB's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ENOB is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: ENOB is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ENOB's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ENOB is overvalued based on its PB Ratio (3.9x) compared to the US Biotechs industry average (2.8x).


Future Growth

How is Enochian Biosciences forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

9.4%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Enochian Biosciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Enochian Biosciences performed over the past 5 years?

-29.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ENOB is currently unprofitable.

Growing Profit Margin: ENOB is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ENOB is unprofitable, and losses have increased over the past 5 years at a rate of 29.4% per year.

Accelerating Growth: Unable to compare ENOB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ENOB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11%).


Return on Equity

High ROE: ENOB has a negative Return on Equity (-20.8%), as it is currently unprofitable.


Financial Health

How is Enochian Biosciences's financial position?


Financial Position Analysis

Short Term Liabilities: ENOB's short term assets ($15.5M) exceed its short term liabilities ($1.2M).

Long Term Liabilities: ENOB's short term assets ($15.5M) do not cover its long term liabilities ($15.9M).


Debt to Equity History and Analysis

Debt Level: ENOB has more cash than its total debt.

Reducing Debt: Insufficient data to determine if ENOB's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ENOB has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: ENOB has less than a year of cash runway if free cash flow continues to reduce at historical rates of 40.6% each year


Dividend

What is Enochian Biosciences's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ENOB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ENOB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ENOB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ENOB's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ENOB's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.8yrs

Average management tenure


CEO

Mark Dybul (58 yo)

2.83yrs

Tenure

US$430,000

Compensation

Honorable Dr. Mark R. Dybul, M.D., serves as Chief Executive Officer at Enochian Biosciences, Inc. since July 1, 2021. He served as Executive Vice-Chair of Enochian Biosciences Inc. since January 7, 2019....


CEO Compensation Analysis

Compensation vs Market: Mark's total compensation ($USD430.00K) is below average for companies of similar size in the US market ($USD2.29M).

Compensation vs Earnings: Mark's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: ENOB's management team is considered experienced (2.8 years average tenure).


Board Members

Experienced Board: ENOB's board of directors are considered experienced (3.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 12%.


Top Shareholders

Company Information

Enochian Biosciences, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Enochian Biosciences, Inc.
  • Ticker: ENOB
  • Exchange: NasdaqCM
  • Founded: 2017
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$655.357m
  • Shares outstanding: 52.22m
  • Website: https://www.enochianbio.com

Number of Employees


Location

  • Enochian Biosciences, Inc.
  • Century City Medical Plaza
  • Suite 906
  • Los Angeles
  • California
  • 90067-2012
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/12/01 00:13
End of Day Share Price2021/11/30 00:00
Earnings2021/09/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.